Natera develops and sells molecular diagnostic tests used across multiple medical areas. Its offerings include blood tests for monitoring cancer recurrence and treatment response, tissue-based genomic profiling for cancer assessment, prenatal screening tests for chromosomal and genetic abnormalities, carrier screening for hereditary conditions, miscarriage analysis, transplant rejection monitoring, and kidney disease testing. The company distributes its tests through direct sales to laboratories, medical centers, physician practices, and pharmaceutical companies, as well as through a cloud-based software platform licensed to partners, and maintains a partnership with BGI Genomics for assay development and commercialization.
1Y: 320.45 (+53.0%) · range 182.65–436.00
entry readiness 55 · MODERATE · exit proximity 0
Value area 268.73–437.41 · 50% of 120d volume overhead · moderate overhead
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -14.59% | -14.59% | 1/20d |
| 40d | -14.59% | -14.59% | 1/40d |